Medicament dispenser

• US 20050039743A1
• Filed: 12/20/2002
• Published: 02/24/2005
• Est. Priority Date: 12/22/2001
• Status: Abandoned Application

• Current Assignee: Glaxo Group Limited (GSK plc)
• Original Assignee: Glaxo Group Limited (GSK plc)
• Inventors: Taylor, Anthony James
• Application Number:
  US10/499,222
• Publication Number:
  US 20050039743A1
• Time in Patent Office: Days
• US Class Current: 128/203.150
• CPC Class Codes: A61M 15/0043 Non-destructive separation of the package, e.g. peeling
• CPC Class Codes: A61M 15/0045 using multiple prepacked dosages on a same carrier, e.g. blisters
• CPC Class Codes: A61M 15/0051 the dosages being arranged on a tape, e.g. strips
• CPC Class Codes: A61M 15/0055 the used dosages being coiled
• CPC Class Codes: A61M 15/0065 Inhalators with dosage or measuring devices A61M15/0028 takes precedence; dosage devices incorporated in aerosol cans B65D83/52
• CPC Class Codes: A61M 2202/064 Powder
• CPC Class Codes: A61M 2205/0233 Conductive materials, e.g. antistatic coatings for spark prevention
• CPC Class Codes: A61M 2209/06 Packaging for specific medical equipment
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system

Abstract

There is provided a medicament container or delivery device for use with medicament in dry powder form comprising a material that reduces the surface energy or increases the electrical conductivity of some or all parts of the medicament container or delivery device which come into contact with said dry powder form medicament. Suitably, the material has friction-reducing or electrical conductivity-enhancing properties.

Claims

1. A medicament container containing medicament in dry powder form, said medicament container comprising a material that reduces the surface energy or increases the electrical conductivity of some or all parts of the medicament container which come into contact with said dry powder form medicament, wherein the medicament container is in the form of a capsule or blister pack and with the proviso that said material is free from desiccant.

2. A medicament container according to claim 1, wherein said material coats said some or all parts of the medicament container which come into contact with said dry powder form medicament.

3. A medicament container according to claim 1, wherein said material incorporates into the some or all parts of the medicament container which come into contact with said dry powder form medicament.

4. A medicament container according to claim 1, wherein the material is a friction-reducing material that acts such as to reduce the surface energy of the some or all parts of the medicament container which come into contact with the dry powder form medicament.

5. A medicament container according to claim 4, wherein said surface energy is reduced such as to give a contact angle of greater than about 70 degrees, preferably greater than about 100 degrees.

6. A medicament container according to claim 1, wherein the material comprises a fluoropolymer.

7. A medicament container according to claim 6, wherein said fluoropolymer is selected from the group consisting of tetrafluoroethylene (PTFE), fluorinated ethylene propylene (FEP), perfluoroalkoxyalkane (PFA), ethylene tetrafluoroethylene (ETFE), vinyldienefluoride (PVDF), chlorinated ethylene tetrafluoroethylene and any mixtures thereof.

8. A medicament container according to claim 7, wherein the fluoropolymer is blended with a non-fluorinated polymer selected from the group consisting of polyamides, polyimides, polyamide imides, polyethersulfones, polyphenylene sulfides, and amine-formaldehyde thermosetting resins.

9. A medicament container according to claim 6, wherein the fluoropolymer is applied by surface treatment of the medicament container.

10. A medicament container according to claim 9, wherein said surface treatment comprises a process of plasma coating.

11. A medicament container according to claim 10, wherein said process of plasma coating employs fluorinated small molecules selected from the group consisting of C_1-10perfluoroalkanes, C_2-10perfluoroalkenes and any mixtures thereof.

12. A medicament container according to claim 10, wherein said process of plasma coating is by interchange of hydrogen ions at the surface of the container or delivery device with fluorine ions.

13. A medicament container according to claim 10, wherein the plasma coating process is selected from the group consisting of a microwave plasma process, a pulsed wave plasma process and a hot filament chemical vapour process.

14. A medicament container according to claim 1, wherein said material is a conductivity-enhancing material that acts such as to enhance the electrical conductivity of the some or all parts of the medicament container which come into contact with the dry powder form medicament.

15. A medicament container according to claim 14, wherein the conductivity-enhancing material is a ceramic material.

16. A medicament container according to claim 15, wherein said ceramic material comprises a composite of a ceramic material with a conductive metal or a ceramic material doped with a conductive metal.

17. A medicament container according to claim 15, wherein the conductivity-enhancing material comprises an organic polymeric material.

18. A medicament container according to claim 17, wherein said organic polymeric material is selected from the group consisting of polycarbonate, polyester, acetal, nylon and epoxy resins.

19. A medicament container according to claim 17, wherein the organic polymeric material includes a doping element selected from the group consisting of gold, silver and similar precious metals, carbon black and quaternary ammonium salts.

20. A medicament container according to claim 1, wherein the dry powder medicament is suitable for the treatment of a respiratory disorder.

21. A medicament container according to claim 20, wherein said dry powder medicament is selected from the group consisting of albuterol, salmeterol, fluticasone propionate and beclomethasone dipropionate and salts or solvates thereof and any mixtures thereof.

22. A medicament container according to claim 21, wherein the dry powder medicament comprises a combination of fluticasone propionate and salmeterol xinafoate.

23. An inhalation device comprising a body defining a chamber for receipt of a dry powder medicament container according to claim 1 and an outlet in communication with said chamber for release of the medicament.